Health Administration owns or works fifty-nine hospitals in fifteen states with approximately 8,900 certified beds. This collaboration will allow Health Management to provide: The ability to implement audit equipment to make sure that quality standards are being met and safety precautions are being complied with while both are used to additional educate caregivers at Health Management’s hospitals to continually enhance quality and protection for their patients. Doctors, nurses and other healthcare providers having the ability to and cost-effectively monitor effectively, treat and visit their patients.There is significant value and opportunity in this hyperoxaluria portfolio and a genuine patient need for an effective treatment. We realize the Allena group and feel they are best outfitted to translate the potential of the portfolio and the previous clinical findings into a brand-new and novel proteins therapy, stated Magda Marquet, Ph.D., founder and co-chairman of Althea Technology. We are looking towards working closely with the Allena team to aid the development of ALLN-177. We’ve moved quickly and effectively to prepare ALLN-177 for clinical trials in sufferers with hyperoxaluria, said Robert Gallotto, co-founder and chief working officer of Allena Pharmaceuticals.